Affinage

PRMT1

Protein arginine N-methyltransferase 1 · UniProt Q99873

Length
371 aa
Mass
42.5 kDa
Annotated
2026-06-10
100 papers in source corpus 64 papers cited in narrative 64 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PRMT1 is the predominant mammalian type I protein arginine methyltransferase, catalyzing arginine monomethylation and asymmetric dimethylation of histone and non-histone substrates to regulate transcription, RNA processing, signal transduction, DNA damage response, innate immunity, and metabolic reprogramming (PMID:9545638, PMID:31451547). Its catalytic activity requires homodimerization through a dimerization arm—cancer-associated mutations in this arm (W215L, Y220N, M224V) abolish oligomer formation and impair SAM binding and turnover (PMID:34688662)—and is allosterically stimulated by direct interaction with PRMT2 (PMID:21851090) while being repressed by reversible oxidation of active-site cysteines to sulfenic acid (PMID:25911106) and by TR3 binding to the catalytic domain (PMID:19095693). On chromatin, PRMT1 deposits H4R3me2a to open chromatin and drive lineage- and stimulus-specific transcriptional programs, recruiting the SWI/SNF ATPase SMARCA4 as an effector (PMID:33853662), maintaining DNMT1 enhancer activity to silence endogenous retroviruses (PMID:37991725), and sustaining β-cell identity, adipogenesis, and inducible cytokine genes (PMID:31848151, PMID:35921899, PMID:35040433). Beyond histones, PRMT1 methylates a large repertoire of substrates—including EGFR, FLT3-ITD, CaMKII, SMAD7, EZH2, CDK4, cGAS, TBK1, PHGDH, PGK1, ATF4, SRSF1, and TDP-43—frequently engaging in cross-talk with phosphorylation, ubiquitylation, and other modifications to control protein stability, activity, complex assembly, and localization (PMID:26571401, PMID:31217189, PMID:30504773, PMID:32895488, PMID:37193698, PMID:34551290, PMID:36823188, PMID:39817908). Many substrates are accessed through adaptor proteins (BTG2 for CDK4, GFI1 for MRE11/53BP1) (PMID:28628091, PMID:29651020), and substrate selectivity at H4R3 is tuned by neighbouring histone marks such as H4S1 phosphorylation and H4K5 acetylation (PMID:33380261). PRMT1 itself is positioned by upstream signaling: CDK5 phosphorylation at S307 drives nucleocytoplasmic/lysosomal translocation toward mTORC1 activation (PMID:36995937), K145 acetylation arrests it in the cytoplasm (PMID:38605214), and its abundance is set by FBXO7-mediated K37 ubiquitylation and p53/USP7-dependent degradation (PMID:38839752, PMID:39009589). Through these activities PRMT1 functions as a context-dependent driver of cancer cell proliferation, metabolic flux, chemoresistance, and immune evasion, and conversely protects cardiomyocytes from CaMKII hyperactivation and ER stress (PMID:38383964, PMID:38401121, PMID:30504773, PMID:31787756).

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 1998 High

    Established the founding identity of the human protein as a bona fide arginine methyltransferase rather than an uncharacterized ORF.

    Evidence In vitro methyltransferase assay with recombinant protein plus complementation of a yeast HMT1 mutant

    PMID:9545638

    Open questions at the time
    • Did not identify physiological substrates
    • No structure or catalytic mechanism defined
    • Symmetric vs asymmetric product specificity not resolved
  2. 1999 Medium

    Linked PRMT1 to a defined receptor pathway by showing it binds the IFNAR-1 cytoplasmic tail and supports type I interferon responses.

    Evidence Co-IP with IFNAR chains plus antisense knockdown with VSV and growth assays

    PMID:10090404

    Open questions at the time
    • No methylation substrate at the receptor identified
    • Binding specificity not structurally mapped
  3. 2008 Medium

    Defined PRMT1 as a transcriptional coactivator recruited to target promoters and as a target of allosteric inhibition by an interacting orphan receptor.

    Evidence ChIP, reporter assays, and co-IP for STAT5/CITED2 coactivation; reciprocal TR3 interaction with catalytic-domain inhibition and substrate methylation changes

    PMID:18413343 PMID:19095693

    Open questions at the time
    • Direct histone marks at coactivated promoters not measured in STAT5 work
    • TR3 inhibitory binding site not mapped at residue level
  4. 2011 High

    Showed PRMT1 activity is positively regulated by protein-protein interaction, establishing PRMT2 as an allosteric stimulator.

    Evidence Co-IP, BiFC, in vitro kinetics with domain deletions and active-site mutagenesis

    PMID:21851090

    Open questions at the time
    • Physiological context of PRMT1-PRMT2 modulation not defined
    • No structure of the stimulated complex
  5. 2015 High

    Expanded PRMT1 into non-histone substrate biology, demonstrating methylation that controls substrate stability, receptor signaling, and splicing-factor function.

    Evidence In vitro methylation, mutagenesis, ubiquitylation/RNA-IP/rescue, and xenografts for RBM15 (R578) and EGFR (R198/R200)

    PMID:26571401 PMID:26575292

    Open questions at the time
    • Generality of methylation-coupled degradation across substrates unknown
    • Extracellular EGFR methylation topology not structurally explained
  6. 2015 Medium

    Identified redox sensing as a post-translational control of PRMT1, distinct from expression-level regulation.

    Evidence In vitro activity assay with H2O2 dose-response and reversible cysteine oxidation detection

    PMID:25911106

    Open questions at the time
    • Oxidized cysteine residues not definitively mapped to active site
    • In vivo redox regulation not demonstrated
  7. 2017 High

    Demonstrated adaptor-dependent substrate selection and lineage-specific transcriptional control, with in vivo conditional-knockout validation.

    Evidence BTG2-facilitated CDK4 methylation with cell-cycle assays; conditional Prmt1 KO with ChIP linking Eya1 methylation to MyoD induction

    PMID:27849571 PMID:28628091

    Open questions at the time
    • Methylated residues on CDK4 and Eya1 not fully mapped
    • How adaptors confer specificity mechanistically unresolved
  8. 2018 High

    Established PRMT1 as a regulator of signaling, DNA repair, and developmental transitions through substrate methylation and adaptor recruitment, with physiological consequences in heart.

    Evidence Cardiac KO with CaMKII methylation and pharmacological rescue; SMAD7 methylation in TGF-β/EMT; GFI1-dependent methylation of MRE11/53BP1

    PMID:29651020 PMID:29907569 PMID:30504773

    Open questions at the time
    • MRE11/53BP1 methylation sites and DDR mechanism not fully defined
    • SMAD7 methylation site not pinpointed in this study
  9. 2019 High

    Defined PRMT1 as a global regulator of RNA metabolism and a context-specific cancer dependency, and quantified its methylproteome.

    Evidence Proteomic ADMA profiling (18 high-confidence substrates; ADMA-to-SDMA switching), translation-initiation and FLT3-ITD/AML KO models, CRISPR PRMT1/PRMT5 synthetic lethality

    PMID:28655788 PMID:30916320 PMID:31217189 PMID:31451547

    Open questions at the time
    • Functional consequence of most ADMA sites untested
    • Mechanism of ADMA/SDMA scavenging interplay incomplete
  10. 2019 High

    Extended PRMT1 control to stress-granule dynamics, nuclear receptor non-genomic signaling, ER-stress protein stability, and chromatin accessibility for cell identity.

    Evidence UBAP2L RGG methylation/SG assays; IGF-1R-bound PRMT1 methylating ERα R260; ATF4 R239 methylation with cardiac KO; β-cell KO with ChIP-seq/ATAC-seq linking H4R3me2a to open chromatin

    PMID:30692633 PMID:31114027 PMID:31787756 PMID:31848151

    Open questions at the time
    • How a single enzyme balances nuclear vs cytoplasmic substrate pools not resolved here
    • Direct vs indirect chromatin opening by H4R3me2a not separable in KO
  11. 2020 High

    Resolved the structural basis of PRMT1 inhibitor selectivity and dimerization-dependent catalysis, and showed neighbouring histone marks tune substrate choice.

    Evidence Crystal structures/ITC of PRMT1 with bisubstrate inhibitors; dimerization-arm mutants with biophysics and activity; modified H4 peptide kinetics

    PMID:32011657 PMID:33380261

    Open questions at the time
    • Full enzyme-substrate complex structures for non-histone substrates lacking
    • Dynamics of dimer assembly in cells not measured
  12. 2020 Medium

    Showed PRMT1 chromatin recruitment and translocation are signal-driven, coupling DNA damage and Golgi/secretory functions to its methyltransferase activity.

    Evidence DNA-PK-mediated recruitment/phosphorylation directing H4R3me2a at SASP genes; SCYL1 methylation with Golgi colocalization and neurite-outgrowth rescue; Mdm4 splicing control in epicardium

    PMID:31995759 PMID:32521264 PMID:32583741

    Open questions at the time
    • PRMT1 phosphosite targeted by DNA-PK not identified
    • SCYL1 methylation site not fully defined
  13. 2021 High

    Consolidated PRMT1 as a hub coupling histone marks to effector recruitment and as a stabilizer/activator of chromatin and immune-signaling proteins.

    Evidence H4R3me2a-dependent SMARCA4 recruitment; EZH2 R342 methylation cross-talk stabilizing protein and promoting PRC2 assembly; TBK1 methylation (R54/R134/R228) with myeloid KO viral susceptibility; PDAC RNA-metabolism dependency

    PMID:32895488 PMID:33853662 PMID:34330913 PMID:34551290 PMID:34775498

    Open questions at the time
    • How H4R3me2a is read by SMARCA4 structurally unknown
    • Substrate prioritization during infection not defined
  14. 2022 Medium

    Expanded PRMT1 into immune-cell programming, adipogenesis, hepatic metabolism, and additional substrate-stability/stemness axes.

    Evidence H4R3me2a at IL-2 promoter for CD8+ polyfunctionality; PPARγ/C/EBPβ control in adipogenesis; catalytic-mutant-validated PGC-1α/HNF-4α hepatic FAO; EphA2-PRMT1-SOX2 stemness

    PMID:35040433 PMID:35401831 PMID:35921899 PMID:36377249

    Open questions at the time
    • Direct vs indirect targets in metabolic programs incompletely separated
    • SOX2 methylation site not mapped
  15. 2023 High

    Defined PRMT1 as a brake on innate-immune and necroptotic signaling and a driver of metabolic and m6A-related reprogramming, with translational implications for immunotherapy.

    Evidence cGAS R133 methylation blocking dimerization/STING; RIP3 R486 methylation suppressing necrosome; PHGDH R236 activation; WTAP and METTL14 methylation regulating m6A; DNMT1-enhancer H4R3me2a controlling ERV/IFN; BRD4, c-Fos, NONO methylation

    PMID:33420374 PMID:36823188 PMID:37005412 PMID:37193698 PMID:37269817 PMID:37558663 PMID:37564212 PMID:37737256 PMID:37991725

    Open questions at the time
    • Selectivity that determines which substrate dominates in a given tumor context unresolved
    • Reader-mediated outputs (e.g., SPF30) functionally underexplored
  16. 2024 High

    Mapped upstream control of PRMT1 abundance and localization and detailed its role in metabolic flux, mitochondrial fate, and immune evasion.

    Evidence FBXO7 K37 ubiquitylation; CDK5-S307 phosphorylation driving translocation and WDR24/mTORC1 activation; K145 acetylation (LPCAT2) cytoplasmic arrest controlling SLC7A11/ferroptosis; PHGDH R54/R20, PGK1 R206, DDX3 methylation; STAT1/MHC-I suppression; nuclear MAFF/BACH1 restraint

    PMID:36995937 PMID:38383964 PMID:38401121 PMID:38402202 PMID:38605214 PMID:38691454 PMID:38839752 PMID:39042374

    Open questions at the time
    • Integration of competing localization signals (phospho/acetyl) not unified mechanistically
    • Causal hierarchy among multiple metabolic substrates unclear
  17. 2025 High

    Connected PRMT1 to neurodegenerative proteostasis by showing methylation controls phase separation and aggregation of an ALS-relevant substrate.

    Evidence TDP-43 R293 in vitro methylation, LLPS and aggregation assays, p38α phospho cross-talk, ALS patient-derived motor neurons

    PMID:39817908

    Open questions at the time
    • Therapeutic modulation of this axis in vivo untested
    • Stoichiometry of methylation vs phosphorylation in patient tissue unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how PRMT1 selects among its very large substrate repertoire in a given cell, and how its competing localization, modification, and degradation signals are integrated into context-specific outputs.
  • No unifying model for substrate prioritization across nucleus, cytoplasm, Golgi, ER, and mitochondria
  • Quantitative occupancy and stoichiometry of most methylation sites in vivo unknown
  • Adaptor- vs intrinsic-specificity contributions not systematically dissected

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 10 GO:0140096 catalytic activity, acting on a protein 10 GO:0042393 histone binding 4 GO:0140110 transcription regulator activity 4 GO:0098772 molecular function regulator activity 3
Localization
GO:0005634 nucleus 6 GO:0000228 nuclear chromosome 3 GO:0005829 cytosol 3 GO:0005783 endoplasmic reticulum 1 GO:0005794 Golgi apparatus 1
Pathway
R-HSA-8953854 Metabolism of RNA 6 R-HSA-1430728 Metabolism 5 R-HSA-162582 Signal Transduction 5 R-HSA-74160 Gene expression (Transcription) 5 R-HSA-168256 Immune System 4 R-HSA-4839726 Chromatin organization 4 R-HSA-1640170 Cell Cycle 3 R-HSA-5357801 Programmed Cell Death 3 R-HSA-73894 DNA Repair 2
Partners
EGFREZH2FLT3GFI1IGF1RPRMT2TBK1TR3

Evidence

Reading pass · 64 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1998 Recombinant HRMT1L2 (PRMT1) protein exhibits arginine methyltransferase activity in vitro and complements a yeast HMT1 mutant strain in vivo, establishing it as a functional human arginine methyltransferase. In vitro methyltransferase assay with recombinant protein; yeast complementation assay Genomics High 9545638
1999 PRMT1 binds specifically to the intracytoplasmic domain of the IFNAR-1 chain of the type I interferon receptor (not IFNAR-2 or PRMT2), and reduced PRMT1 expression diminishes the antiviral and antiproliferative effects of IFN-β. Co-immunoprecipitation; antisense-mediated knockdown with VSV replication assay and cell growth inhibition assay Journal of interferon & cytokine research Medium 10090404
2008 PRMT1 and CARM1 cooperate as coactivators of STAT5-dependent transcription; cytokine stimulation induces a physical association between STAT5 and both PRMTs, and both enzymes are recruited to the CITED2 gene promoter as direct co-activators. siRNA double knockdown; cDNA microarray; ChIP; reporter gene assay; co-immunoprecipitation Nucleic acids research Medium 18413343
2008 PRMT1 physically interacts with orphan receptor TR3 and stabilizes TR3 protein (independent of methyltransferase activity), enhancing TR3 transcriptional activity; reciprocally, TR3 binding to the catalytic domain of PRMT1 inhibits PRMT1 methyltransferase activity, altering methylation of PRMT1 substrates STAT3 and Sam68. Co-immunoprecipitation; methyltransferase activity assay; luciferase reporter assay; TR3-knockdown cells and TR3-knockout mice Nucleic acids research Medium 19095693
2011 PRMT1 and PRMT2 directly interact, and this interaction stimulates PRMT1 methyltransferase activity (increased Vmax and altered Km); complex formation requires full-length active PRMT1 and the SH3 domain of PRMT2 contributes to a methylation-dependent interaction. Co-immunoprecipitation; bimolecular fluorescence complementation; in vitro methyltransferase assays; active-site mutagenesis and domain deletions Biochemistry High 21851090
2015 PRMT1 methylates RBM15 at R578, promoting its ubiquitylation by E3 ligase CNOT4 and subsequent proteasomal degradation; reduced RBM15 protein impairs recruitment of splicing factor SF3B1 to intronic regions of megakaryopoiesis genes (GATA1, RUNX1, TAL1, c-MPL), thereby regulating alternative splicing. Co-immunoprecipitation; in vitro methylation assay; ubiquitylation assay; RNA-IP; rescue experiments with RBM15 overexpression eLife High 26575292
2015 PRMT1 methylates EGFR at R198 and R200 of the extracellular domain, enhancing EGF binding, receptor dimerization, and downstream signaling; methylation-defective EGFR mutants reduce tumor growth and restore sensitivity to cetuximab. In vitro methylation assay; site-directed mutagenesis; binding assay; mouse orthotopic colorectal cancer xenograft model The Journal of clinical investigation High 26571401
2015 PRMT1 enzymatic activity is inhibited under oxidative conditions via cysteine oxidation to sulfenic acid (-SOH); this inhibition is reversible by reduction, representing a redox-sensitive regulatory mechanism distinct from changes in protein expression. In vitro methyltransferase activity assay; hydrogen peroxide dose-response; cysteine oxidation detection The Journal of biological chemistry Medium 25911106
2015 PRMT1 and PRMT8 act as selective modulators of retinoic acid receptor (RAR/RXR) transcriptional activity in neuronal differentiation; loss of either reduces nuclear arginine methylation and dysregulates neuronal gene expression, affecting neuronal cell fate. siRNA knockdown; RNA-seq; neuronal differentiation model of murine ESCs; electrophysiology Stem cells (Dayton, Ohio) Medium 25388207
2017 PRMT1 methylates CDK4, preventing formation of the CDK4-Cyclin-D3 complex and thereby inducing cell cycle arrest in pre-B cells; BTG2 acts as an adaptor facilitating PRMT1 methylation of CDK4. Co-immunoprecipitation; in vitro methylation assay; cell cycle analysis; in vitro and in vivo proliferation assays with BCR-ABL1-transformed pre-B cells Nature immunology High 28628091
2017 PRMT1 methylates the transcriptional co-activator Eya1, and loss of PRMT1 in muscle stem cells prevents Eya1 methylation, reducing Eya1 recruitment to the MyoD promoter and suppressing Eya1/Six1-dependent MyoD expression, thereby impairing muscle stem cell differentiation. In vitro methylation assay; conditional Pax7CreERT2-driven Prmt1 knockout; ChIP; co-immunoprecipitation Molecular and cellular biology High 27849571
2017 PRMT1 depletion impairs arginine methylation of the translation initiation complex, disrupting its assembly and inhibiting cap-dependent translation; this represents a critical vulnerability in p53-deficient cancer cells. shRNA screen; mechanistic proteomics; translation initiation complex assembly assay; in vitro and in vivo tumor models Cancer research Medium 28655788
2018 PRMT1 methylates CaMKII at R9 and R275, inhibiting CaMKII activity; cardiac-specific PRMT1 deletion leads to CaMKII hyperactivation, dilated cardiomyopathy and heart failure, which is rescued by pharmacological CaMKII inhibition. Cardiac-specific Prmt1 knockout mice; in vitro methylation assay; co-immunoprecipitation; CaMKII activity assay; pharmacological rescue Nature communications High 30504773
2018 PRMT1 methylates SMAD7 at the TGF-β receptor complex, promoting SMAD7 dissociation from receptors and enabling TGF-β-induced SMAD3 activation; this mechanism is required for TGF-β-induced EMT and epithelial stem-cell generation. In vitro methylation assay; co-immunoprecipitation; siRNA knockdown; EMT and stem-cell functional assays The Journal of biological chemistry Medium 29907569
2018 GFI1 interacts with PRMT1 and its substrates MRE11 and 53BP1, enabling PRMT1 to bind and methylate these DNA repair proteins; GFI1 loss abolishes PRMT1-dependent methylation of MRE11 and 53BP1 and causes defective DNA damage response. Co-immunoprecipitation; in vitro methylation assay; GFI1 knockout T cells; ionizing radiation sensitivity assay Nature communications Medium 29651020
2018 RANKL treatment increases PRMT1 expression and promotes its nuclear localization in bone marrow-derived macrophages via JNK-dependent signaling; PRMT1 directly interacts with NF-κB and regulates its transcriptional activity during osteoclastogenesis. siRNA knockdown; PRMT1 haploinsufficient cells; co-immunoprecipitation; TRAP staining; in vivo OVX mouse model Experimental & molecular medicine Medium 30154485
2019 PRMT1 methylates FLT3-ITD at R972/R973; this methylation promotes AML maintenance and cross-talks with FLT3 phosphorylation at Y969; importantly, FLT3 methylation persists following kinase inhibitor treatment, indicating independence from kinase activity. Co-immunoprecipitation; in vitro methylation assay; PRMT1-knockout mouse; patient-derived xenograft and murine AML models; combined inhibitor treatment Blood High 31217189
2019 PRMT1 asymmetrically dimethylates UBAP2L at its RGG motif; increased arginine methylation of UBAP2L blocks its interactions with stress granule (SG) components (mRNPs, RBPs, ribosomal subunits), preventing SG assembly, while decreased methylation promotes SG assembly. In vitro methylation assay; stress granule assembly/disassembly assays; immunofluorescence; co-immunoprecipitation Cell death and differentiation Medium 31114027
2019 PRMT1 methylates SRSF1, and this methylation is required for SRSF1 binding with RNA; in the absence of PRMT1, SRSF1 methylation and SRSF1-dependent splicing functions are impaired. In vitro methylation assay; RNA-binding assay; siRNA knockdown; splicing reporter assay Journal of hematology & oncology Low 22839530
2019 Loss of PRMT1 sensitizes cells to PRMT5 inhibition; MTAP-deleted cells with attenuated PRMT5-MEP50 signaling are more sensitive to PRMT1 inhibition, demonstrating functional redundancy between PRMT1 (asymmetric methylation) and PRMT5 (symmetric methylation) pathways. CRISPR/Cas9 genetic screen; pharmacological inhibitor combination; cell viability assay Nucleic acids research Medium 30916320
2019 PRMT1 is constitutively bound to IGF-1R and becomes activated upon IGF-1 stimulation; activated PRMT1 methylates ERα at R260, triggering formation of the mERα/Src/PI3K complex and non-genomic IGF-1 signaling in breast cancer cells. Co-immunoprecipitation; in vitro methylation assay; PRMT1 inhibition/knockdown; signaling pathway analysis Oncogene Medium 30692633
2019 PRMT1 methylates ATF4 at R239, stabilizing ATF4 protein; ATF4 methylation-deficient mutant R239K exacerbates ER stress and apoptosis in cardiomyocytes; PRMT1 null hearts show exacerbated ER stress. In vitro methylation assay; site-directed mutagenesis; PRMT1 conditional knockout heart; ER stress markers Cell death & disease High 31787756
2019 PRMT1 is required for maintaining β-cell identity; PRMT1-dependent H4R3me2a increases chromatin accessibility at CTCF and β-cell transcription factor binding sites, as revealed by ChIP-seq and ATAC-seq in β-cell-specific Prmt1 knockout mice. β-cell-specific Prmt1 knockout; ChIP-seq; ATAC-seq; gene expression profiling Diabetes High 31848151
2019 Deep proteomic methylation profiling identified 18 high-confidence PRMT1 substrates; PRMT1 knockdown caused significant loss of asymmetric dimethylarginine (ADMA) marks on 78 proteins enriched for mRNA metabolic processes; some sites (e.g., HNRNPA1 R206) switch from ADMA to SDMA upon PRMT1 knockdown, revealing dynamic interplay between methyltransferases. Immunoaffinity purification and strong cation exchange enrichment; mass spectrometry; PRMT1 knockdown Molecular & cellular proteomics : MCP Medium 31451547
2019 Alcohol induces PRMT1 dephosphorylation at S297; phosphorylation at S297 is necessary for PRMT1-dependent protein arginine methylation and regulation of pro-inflammatory and pro-apoptotic gene expression, while oxidative stress response gene regulation is phosphorylation-independent. AAV-Cre-mediated hepatocyte-specific PRMT1 knockout; phosphorylation mimic/null mutants (S297A, S297D); gene expression analysis; in vitro methyltransferase assay Scientific reports Medium 31235809
2020 PRMT1 is recruited to chromatin by DNA-PK in response to cisplatin; DNA-PK phosphorylates PRMT1, directing its enzymatic activity toward H4R3 (producing H4R3me2a) at pro-inflammatory gene promoters, thereby sustaining the senescence-associated secretory phenotype (SASP). Mass spectrometry-based proteomics; co-immunoprecipitation; ChIP; H4R3me2a chromatin profiling; clonogenic assay Cell reports Medium 31995759
2020 PRMT1 regulates Mdm4 pre-mRNA splicing; loss of PRMT1 shifts Mdm4 splicing toward a shorter isoform, leading to p53 accumulation, enhanced Slug degradation, and blockade of EMT in epicardial cells. Epicardial-specific Prmt1 deletion; scRNA-seq; splicing analysis; p53 pathway readouts; in vivo epicardial invasion assay Cell reports Medium 32521264
2020 PRMT1 methylates EZH2 at R342 (meR342-EZH2); this methylation inhibits CDK1-mediated phosphorylation at EZH2 T345 and T487, thereby attenuating TRAF6-mediated ubiquitylation and increasing EZH2 protein stability. In vitro methylation assay; co-immunoprecipitation; phosphorylation and ubiquitylation assays; site-directed mutagenesis Cell death and differentiation High 32895488
2020 PRMT1 methylates SCYL1 at the γ2-COP binding site; this methylation is required for SCYL1 interaction with γ2-COP and COPI vesicle function; PRMT1 colocalizes with SCYL1 in the Golgi fraction, and inhibition of PRMT1 causes abnormal Golgi morphology and impairs axon and dendrite outgrowth. In vitro methylation assay; co-immunoprecipitation; subcellular fractionation; siRNA knockdown; neurite outgrowth assay; rescue with methylation-site SCYL1 mutant Molecular biology of the cell High 32583741
2020 PRMT1 suppresses doxorubicin-induced cardiotoxicity; doxorubicin induces PRMT1 translocation to the endoplasmic reticulum, where PRMT1 methylates ATF4 to suppress the PERK/ATF4/CHOP proapoptotic ER stress pathway. PRMT1 overexpression/depletion in H9c2 cardiomyocytes; subcellular fractionation/translocation assay; ER stress marker analysis; in vitro methylation assay Cellular signalling Medium 35863589
2021 PRMT1 methylates NONO at R251; this asymmetric dimethylation promotes colorectal cancer cell proliferation, migration, and invasion; NONO R251K mutant cells show reduced malignant phenotype. Mass spectrometry; in vitro methylation assay; NONO R251K mutant cell lines; PRMT1 knockdown and pharmacological inhibition; xenograft model Oncogene Medium 33420374
2021 PRMT1-mediated H4R3me2a directly recruits SMARCA4 (an ATPase subunit of the SWI/SNF complex) to chromatin; SMARCA4 acts as a novel effector of H4R3me2a and cooperates with PRMT1 to activate EGFR and TNS4 transcription in colorectal cancer cells. Co-immunoprecipitation; ChIP; ChIP-seq; cell proliferation/migration assays; in vivo CRC mouse model Genome medicine Medium 33853662
2021 PRMT1 inhibition in PDAC impairs RNA metabolism including splicing, alternative polyadenylation, and transcription termination, causing downregulation of DNA damage response pathways and promoting genomic instability. RNAi in vivo functional genomics; proteomic and transcriptomic analyses; pharmacological PRMT1 inhibition; patient-derived PDAC models Nature communications Medium 34330913
2021 PRMT1 methylates EZH2 at R342, promoting PRC2 complex assembly by facilitating EZH2 interaction with SUZ12 and preventing AMPKα1-mediated phosphorylation at T311; this results in enhanced H3K27me3 at P16 and P21 promoters and promotes breast cancer cell proliferation. In vitro methylation assay; co-immunoprecipitation; ChIP; site-directed mutagenesis; in vitro and in vivo proliferation assays Cell death & disease Medium 34775498
2021 PRMT1 promotes TBK1 activation by directly interacting with TBK1 and catalyzing asymmetric methylation at R54, R134, and R228; this methylation enhances TBK1 oligomerization and subsequent TBK1 phosphorylation, promoting type I interferon production; myeloid-specific Prmt1 KO mice are more susceptible to viral infection. Co-immunoprecipitation; in vitro methylation assay; site-directed mutagenesis; myeloid-specific Prmt1 knockout mice; viral infection model Cell reports High 34551290
2021 Naturally occurring cancer-associated mutations in the PRMT1 dimerization arm (W215L, Y220N, M224V) disrupt oligomer formation and substantially impair SAM binding and methyltransferase activity, demonstrating that dimerization through the dimerization arm is required for PRMT1 catalytic function. Site-directed mutagenesis; analytical ultracentrifugation; native PAGE; in vitro methyltransferase activity assay; molecular dynamics simulations The Journal of biological chemistry High 34688662
2022 Wnt activation upregulates PRMT1 expression in CD8+ T cells; PRMT1-mediated H4R3me2a deposition at the IL-2 promoter is required for Wnt-induced T cell polyfunctionality and IL-2 production; PRMT1 inhibition abrogates the polyfunctionality effect. Chromatin immunoprecipitation; PRMT1 inhibition; gene expression profiling; cytokine production assay The Journal of clinical investigation Medium 35040433
2022 PRMT1 promotes adipogenesis by catalyzing H4R3me2a to upregulate PPARγ expression; PRMT1 also stabilizes C/EBPβ protein by decreasing the E3 ubiquitin ligase Smurf2 levels, and interacts with C/EBPβ to promote its phosphorylation. Gain and loss of function (siRNA/overexpression); H4R3me2a ChIP; co-immunoprecipitation; ubiquitylation assay; adipogenesis assay in 3T3-L1 and C3H10T1/2 cells The Journal of biological chemistry Medium 35921899
2022 PRMT1 methylates SRSF1, which is critical for SRSF1 phosphorylation, SRSF1 binding to RNA, and exon inclusion; PRMT1 overexpression in breast tumors is associated with increased SRSF1 arginine methylation and aberrant exon inclusion patterns that drive cancer cell growth. PRMT1 methylome profiling; in vitro methylation assay; RNA binding assay; splicing reporter; PRMT1 inhibitor iPRMT1; breast cancer cell growth assay Cell reports High 37938975
2023 PRMT1 methylates cGAS at conserved R133, preventing cGAS dimerization and suppressing cGAS/STING innate immune signaling in cancer cells; genetic or pharmacological PRMT1 ablation activates cGAS/STING-dependent type I and II interferon responses and increases tumor-infiltrating lymphocytes. In vitro methylation assay; site-directed mutagenesis; cGAS dimerization assay; cGAS/STING pathway reporter; in vivo tumor model with anti-PD-1 combination Nature communications High 37193698
2023 PRMT1 methylates PHGDH at R236, activating PHGDH catalytic activity and promoting serine biosynthesis, oxidative stress resistance, and HCC tumor growth; blocking PHGDH methylation with a TAT-tagged peptide inhibits serine synthesis and restrains HCC growth in PDX and xenograft models. In vitro methylation assay; mass spectrometry; PHGDH activity assay; PDX and xenograft mouse models; metabolomics Nature communications High 36823188
2023 CDK5 phosphorylates PRMT1 at S307, promoting its translocation from nucleus to cytoplasm and lysosome; cytoplasmic PRMT1 then methylates WDR24 (a GATOR2 complex component) to activate mTORC1 signaling in response to amino acids. Co-immunoprecipitation; subcellular fractionation; in vitro methylation assay; mTORC1 signaling assay; xenograft tumor model Cell reports Medium 36995937
2023 PRMT1 methylates WTAP (a key m6A methyltransferase complex component); WTAP methylation promotes m6A modification of NDUFS6 mRNA, activating oxidative phosphorylation in multiple myeloma cells. Co-immunoprecipitation; in vitro methylation assay; m6A sequencing; PRMT1 knockdown; OXPHOS functional assay Cell death & disease Medium 37558663
2023 PRMT1 methylates RIP3 at R486 (R479 in mouse), inhibiting RIP3 interaction with RIP1 and suppression of the RIP1-RIP3 necrosome complex, thereby blocking RIP3 phosphorylation and necroptosis activation; methylation-deficient RIP3 promotes necroptosis and tumor immune escape. In vitro methylation assay; co-immunoprecipitation; RIP3 phosphorylation assay; MDSC infiltration assay; clinical sample analysis with RIP3 di-methylation-specific antibody Cell death & disease Medium 37005412
2023 PRMT1 methylates BRD4 at R179/R181/R183 (antagonized by JMJD6 demethylase); PRMT1-mediated BRD4 methylation promotes BRD4 phosphorylation and ovarian cancer invasion; BRD4 R179/181/183K mutant cells show reduced metastasis. In vitro methylation assay; site-directed mutagenesis; co-immunoprecipitation; JMJD6 demethylation assay; invasion and migration assays Cell death & disease Medium 37737256
2023 PRMT1-dependent H4R3me2a at the Dnmt1 enhancer region maintains DNMT1 expression; PRMT1 deficiency reduces DNMT1 levels, activating endogenous retroviral element (ERV) transcription and double-stranded RNA production, which stimulates interferon signaling and anti-tumor CD8+ T cell responses. ChIP; PRMT1 knockout; DNMT1 expression analysis; ERV transcription assay; in vivo tumor model with anti-PD-1 Cancer research Medium 37991725
2023 PRMT1 promotes c-Fos protein stability by methylating c-Fos at R287, protecting it from autophagic degradation; PRMT1-mediated methylation enhances AP-1 transcriptional activity and promotes gastric tumorigenesis. Co-immunoprecipitation; in vitro methylation assay; autophagy flux assay; PRMT1 knockdown; c-Fos stability assay International journal of biological sciences Medium 37564212
2023 PRMT1 asymmetrically methylates METTL14 at two major arginine residues in its C-terminal RGG repeats; this methylation is recognized by reader protein SPF30 and is essential for METTL14 function in catalyzing m6A modification. In vitro methylation assay; co-immunoprecipitation; m6A modification assay; PRMT1 inhibitor MS023; cell proliferation assay Neoplasia (New York, N.Y.) Medium 37269817
2024 FBXO7 binds PRMT1 and promotes its K37 ubiquitination and proteasomal degradation, thereby suppressing PHGDH arginine methylation/activation and serine synthesis in HCC; FBXO7 is downregulated in human HCC and inversely correlates with PRMT1 protein levels. Co-immunoprecipitation; ubiquitylation assay; PHGDH activity assay; in vitro and in vivo HCC models Nature communications Medium 38839752
2024 PRMT1 methylates PHGDH at R54 and R20 (and also PFKFB3 and PKM2), stabilizing PHGDH by suppressing polyubiquitination and activating it by stabilizing 3-phosphoglycerate binding; this drives serine synthesis pathway flux, increases citrate/palmitate via fatty acid synthase, and promotes chemoresistance in TNBC. In vitro methylation assay; 13C metabolic flux analysis; site mutagenesis; protein stability assay; FASN inhibition; clinical specimen IHC with imaging mass spectrometry Cancer research High 38383964
2024 PRMT1 methylates PGK1 at R206; this meR206-PGK1 enhances phosphorylation at S203, inhibiting mitochondrial function and promoting aerobic glycolysis in colorectal cancer cells. In vitro methylation assay; phosphorylation assay; mitochondrial function assay; glycolysis assay; clinical tissue correlation Cell death & disease Medium 38402202
2024 PRMT1 methylates DDX3 to enhance its protein stability and prevent proteasomal degradation; stabilized DDX3 translocates to mitochondria and facilitates PINK1 translation in response to mitochondrial stress, coordinating mitophagy and mitochondrial biogenesis to support breast cancer metastasis. In vitro methylation assay; protein stability assay; mitochondrial fractionation; PINK1 translation assay; in vivo metastasis model Cancer research Medium 39042374
2024 p53 activation under glucose-deficient conditions suppresses USP7 and promotes polyubiquitin-dependent degradation of PRMT1; melatonin-mediated reduction of glucose uptake downregulates PRMT1 via this p53-USP7 axis in p53 wild-type NSCLC. PRMT1 degradation assay; USP7 inhibitor; p53 activation experiments; cell viability assay Cell death & disease Low 39009589
2024 PRMT1 suppresses IFNγ-induced MHC-I expression by limiting STAT1 expression and activation; PRMT1 knockout or pharmacological inhibition (GSK3368715) elevates STAT1 and MHC-I, enhancing CD8+ T cell-mediated tumor killing and potentiating anti-PD-1 immunotherapy. CRISPR-Cas9 epigenetic screen; PRMT1 KO; pharmacological inhibition; STAT1 expression and phosphorylation analysis; CD8+ T cell cytotoxicity assay; in vivo anti-PD-1 combination Cell reports Medium 38401121
2024 PRMT1 methylates PARP1; this methylation promotes PARP1-dependent DNA damage repair and activates NF-κB (P65) signaling, enhancing cancer cell stemness and immune suppression, thereby driving chemoresistance and lung metastasis in TNBC. Mass spectrometry; co-immunoprecipitation; NF-κB signaling assay; in vitro and in vivo metastasis and chemoresistance assays Research (Washington, D.C.) Low 40927753
2025 PRMT1 methylates TDP-43 at R293; R293 methylation permits TDP-43 liquid-liquid phase separation (LLPS) and reduces pathological TDP-43 aggregation; S292 phosphorylation (by p38α) reduces R293 methylation, establishing reciprocal cross-talk between p38α-mediated phosphorylation and PRMT1-mediated methylation in controlling TDP-43 proteinopathy. In vitro methylation assay; site-directed mutagenesis; LLPS assay; TDP-43 aggregation assay; ALS patient-derived motor neurons; p38α inhibition Cell reports High 39817908
2020 PRMT1 is required for PRMT1-dependent expression of FEN1 (a DNA repair endonuclease) via post-translational modification; elevated PRMT1 maintains high FEN1 levels, contributing to DNA repair capacity and drug resistance in lung cancer cells. PRMT1 knockdown; post-translational modification analysis; FEN1 expression and activity assay; drug resistance assay DNA repair Low 32861926
2022 EphA2 directly interacts with PRMT1 (by co-IP and GST pulldown), increases PRMT1 expression and activity; PRMT1 in turn methylates SOX2, promoting stemness and chemoresistance in small-cell lung cancer. Co-immunoprecipitation; GST pulldown; PRMT1 activity assay; in vitro methylation of SOX2; PDX model Cancer science Medium 36377249
2022 PRMT1 promotes hepatic fatty acid oxidation to prevent diet-induced steatosis through methyltransferase activity-dependent induction of PGC-1α mRNA expression via HNF-4α recruitment to the PGC-1α promoter; methyltransferase-defective PRMT1G80R fails to alleviate steatosis. AAV-mediated hepatic PRMT1 overexpression/knockdown; PRMT1G80R catalytic mutant; ChIP (HNF-4α at PGC-1α promoter); fatty acid oxidation assay; diet-induced obese mouse model Theranostics Medium 35401831
2021 TIPE1 binds to the catalytic domain of PRMT1 and inhibits PRMT1-mediated asymmetric dimethylation of STAT3 at R688; loss of this methylation decreases STAT3 transactivation and suppresses osteosarcoma malignancy. Co-immunoprecipitation; in vitro methylation assay; STAT3 transactivation assay; TIPE1 overexpression/knockdown; in vivo osteosarcoma model Cell death & disease Medium 36151091
2020 Crystal structures of CARM1 and PRMT1 bound to bisubstrate inhibitors reveal that a residue differing between CARM1 (Asn-265) and PRMT1 (Tyr-160) affects the side chain conformation of the catalytically important neighboring glutamate; mutagenesis confirms this residue contributes to differential inhibitor binding. X-ray crystallography; isothermal titration calorimetry; methyltransferase activity assay; site-directed mutagenesis The Biochemical journal High 32011657
2020 H4 Ser-1 phosphorylation inhibits PRMT1-catalyzed asymmetric dimethylation of H4R3; H4K5 acetylation reduces PRMT1 catalytic efficiency while enhancing PRMT5-mediated symmetric dimethylation at the same site, revealing that local histone modifications regulate PRMT1 substrate selectivity. In vitro methyltransferase assay using synthetic modified H4 peptides; kinetic analysis Epigenetics High 33380261
2024 LPCAT2 regulates acetylation of PRMT1 at K145, arresting PRMT1 in the cytoplasm of CRC cells; this prevents PRMT1-mediated nuclear activation of the SLC7A11 promoter, thereby reducing SLC7A11 expression, increasing lipid peroxidation, and inducing ferroptosis. scRNA-seq; co-immunoprecipitation; PRMT1 acetylation assay; SLC7A11 promoter luciferase assay; LPCAT2 knockout mice; ferroptosis assay Oncogene Medium 38605214
2024 In gemcitabine-treated PDAC cells, PRMT1 translocates to the nucleus where its methyltransferase activity limits assembly of chromatin-bound MAFF/BACH1 transcriptional complexes; disrupting this axis delays acquired gemcitabine resistance. Genetic and pharmacological PRMT1 inhibition; Cut&Tag chromatin profiling (H3K27Ac, MAFF, BACH1); MAFF genetic silencing; gemcitabine resistance assays Cell reports Medium 38691454

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2015 Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing. eLife 160 26575292
1998 Identification and characterization of two putative human arginine methyltransferases (HRMT1L1 and HRMT1L2). Genomics 152 9545638
2020 Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis. Cell death and differentiation 144 32895488
2015 PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. The Journal of clinical investigation 129 26571401
2023 PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma. Nature communications 116 36823188
2009 The physiological and pathophysiological role of PRMT1-mediated protein arginine methylation. Pharmacological research 114 19643181
2021 PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling. Genome medicine 113 33853662
2021 Structure, Activity, and Function of PRMT1. Life (Basel, Switzerland) 96 34833023
2019 PRMT1 loss sensitizes cells to PRMT5 inhibition. Nucleic acids research 80 30916320
2019 PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD+ acute myeloid leukemia. Blood 78 31217189
2019 UBAP2L arginine methylation by PRMT1 modulates stress granule assembly. Cell death and differentiation 77 31114027
2018 Cardiac specific PRMT1 ablation causes heart failure through CaMKII dysregulation. Nature communications 73 30504773
2023 PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity. Nature communications 72 37193698
2008 The protein arginine methyltransferases CARM1 and PRMT1 cooperate in gene regulation. Nucleic acids research 68 18413343
2018 Arginine methylation of SMAD7 by PRMT1 in TGF-β-induced epithelial-mesenchymal transition and epithelial stem-cell generation. The Journal of biological chemistry 65 29907569
2013 CARM1 and PRMT1 are dysregulated in lung cancer without hierarchical features. Biochimie 64 24211191
2024 FBXO7 ubiquitinates PRMT1 to suppress serine synthesis and tumor growth in hepatocellular carcinoma. Nature communications 62 38839752
2021 PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer. Oncogene 57 33420374
2021 PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Nature communications 57 34330913
2017 Arginine Methylation by PRMT1 Regulates Muscle Stem Cell Fate. Molecular and cellular biology 55 27849571
2020 PRMT1-p53 Pathway Controls Epicardial EMT and Invasion. Cell reports 54 32521264
2020 PRMT1 Is Recruited via DNA-PK to Chromatin Where It Sustains the Senescence-Associated Secretory Phenotype in Response to Cisplatin. Cell reports 53 31995759
2012 Correlation of SRSF1 and PRMT1 expression with clinical status of pediatric acute lymphoblastic leukemia. Journal of hematology & oncology 53 22839530
2021 PRMT1-mediated EZH2 methylation promotes breast cancer cell proliferation and tumorigenesis. Cell death & disease 52 34775498
2018 GFI1 facilitates efficient DNA repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1. Nature communications 52 29651020
2021 PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Theranostics 51 33859753
2024 PRMT1-mediated PGK1 arginine methylation promotes colorectal cancer glycolysis and tumorigenesis. Cell death & disease 49 38402202
2009 Characterization of PRMT1 from Plasmodium falciparum. The Biochemical journal 49 19344311
2019 Deep Protein Methylation Profiling by Combined Chemical and Immunoaffinity Approaches Reveals Novel PRMT1 Targets. Molecular & cellular proteomics : MCP 48 31451547
2017 The BTG2-PRMT1 module limits pre-B cell expansion by regulating the CDK4-Cyclin-D3 complex. Nature immunology 46 28628091
2015 PRMT1 and PRMT8 regulate retinoic acid-dependent neuronal differentiation with implications to neuropathology. Stem cells (Dayton, Ohio) 45 25388207
2015 Redox Control of Protein Arginine Methyltransferase 1 (PRMT1) Activity. The Journal of biological chemistry 44 25911106
2024 PRMT1 Sustains De Novo Fatty Acid Synthesis by Methylating PHGDH to Drive Chemoresistance in Triple-Negative Breast Cancer. Cancer research 43 38383964
2018 PRMT1-Dependent Macrophage IL-6 Production Is Required for Alcohol-Induced HCC Progression. Gene expression 43 30236171
2017 Arginine methylation catalyzed by PRMT1 is required for B cell activation and differentiation. Nature communications 43 29026071
2023 PRMT1 inhibition promotes ferroptosis sensitivity via ACSL1 upregulation in acute myeloid leukemia. Molecular carcinogenesis 42 37144835
2023 PRMT1 methylation of WTAP promotes multiple myeloma tumorigenesis by activating oxidative phosphorylation via m6A modification of NDUFS6. Cell death & disease 42 37558663
2011 A protein arginine N-methyltransferase 1 (PRMT1) and 2 heteromeric interaction increases PRMT1 enzymatic activity. Biochemistry 42 21851090
2021 The protein arginine methyltransferase PRMT1 promotes TBK1 activation through asymmetric arginine methylation. Cell reports 40 34551290
2019 The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer. Oncogene 40 30692633
1999 Involvement of receptor-bound protein methyltransferase PRMT1 in antiviral and antiproliferative effects of type I interferons. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 40 10090404
2008 A feedback regulatory loop between methyltransferase PRMT1 and orphan receptor TR3. Nucleic acids research 38 19095693
2017 Lipotoxicity-Induced PRMT1 Exacerbates Mesangial Cell Apoptosis via Endoplasmic Reticulum Stress. International journal of molecular sciences 36 28671608
2023 The SMARCA4R1157W mutation facilitates chromatin remodeling and confers PRMT1/SMARCA4 inhibitors sensitivity in colorectal cancer. NPJ precision oncology 35 36922568
2023 PRMT1 driven PTX3 regulates ferritinophagy in glioma. Autophagy 34 36647288
2020 PRMT1 is critical to FEN1 expression and drug resistance in lung cancer cells. DNA repair 33 32861926
2020 Protein Arginine Methyltransferase 1 (PRMT1) Selective Inhibitor, TC-E 5003, Has Anti-Inflammatory Properties in TLR4 Signaling. International journal of molecular sciences 32 32357521
2020 LncRNA NNT-AS1 promote glioma cell proliferation and metastases through miR-494-3p/PRMT1 axis. Cell cycle (Georgetown, Tex.) 32 32420808
2019 Hepatocyte PRMT1 protects from alcohol induced liver injury by modulating oxidative stress responses. Scientific reports 32 31235809
2017 PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer. Cancer research 32 28655788
2024 PRMT1 Inhibition Activates the Interferon Pathway to Potentiate Antitumor Immunity and Enhance Checkpoint Blockade Efficacy in Melanoma. Cancer research 31 37991725
2023 Targeting PRMT1-mediated SRSF1 methylation to suppress oncogenic exon inclusion events and breast tumorigenesis. Cell reports 31 37938975
2022 Wnt activation promotes memory T cell polyfunctionality via epigenetic regulator PRMT1. The Journal of clinical investigation 30 35040433
2020 PRMT1 promotes neuroblastoma cell survival through ATF5. Oncogenesis 30 32415090
2020 Roles of protein arginine methyltransferase 1 (PRMT1) in brain development and disease. Biochimica et biophysica acta. General subjects 30 33127433
2024 TRIM25 promotes glioblastoma cell growth and invasion via regulation of the PRMT1/c-MYC pathway by targeting the splicing factor NONO. Journal of experimental & clinical cancer research : CR 29 38303029
2024 Arginine Methylation of DDX3 by PRMT1 Mediates Mitochondrial Homeostasis to Promote Breast Cancer Metastasis. Cancer research 29 39042374
2023 PRMT1 reverts the immune escape of necroptotic colon cancer through RIP3 methylation. Cell death & disease 29 37005412
2022 PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer. Cancers 29 35053470
2022 PRMT1 suppresses doxorubicin-induced cardiotoxicity by inhibiting endoplasmic reticulum stress. Cellular signalling 29 35863589
2019 PRMT1 Is Required for the Maintenance of Mature β-Cell Identity. Diabetes 29 31848151
2024 PRMT1 promotes pancreatic cancer development and resistance to chemotherapy. Cell reports. Medicine 28 38460517
2023 CDK5-PRMT1-WDR24 signaling cascade promotes mTORC1 signaling and tumor growth. Cell reports 28 36995937
2022 Protein arginine methyltransferase PRMT1 promotes adipogenesis by modulating transcription factors C/EBPβ and PPARγ. The Journal of biological chemistry 28 35921899
2019 PRMT1 suppresses ATF4-mediated endoplasmic reticulum response in cardiomyocytes. Cell death & disease 28 31787756
2023 Protection of c-Fos from autophagic degradation by PRMT1-mediated methylation fosters gastric tumorigenesis. International journal of biological sciences 27 37564212
2023 Methylation of BRD4 by PRMT1 regulates BRD4 phosphorylation and promotes ovarian cancer invasion. Cell death & disease 26 37737256
2022 Ligand-independent EphA2 contributes to chemoresistance in small-cell lung cancer by enhancing PRMT1-mediated SOX2 methylation. Cancer science 26 36377249
2020 PRMT1 inhibition induces differentiation of colon cancer cells. Scientific reports 26 33208761
2022 Hepatic PRMT1 ameliorates diet-induced hepatic steatosis via induction of PGC1α. Theranostics 25 35401831
2024 PRMT1 in human neoplasm: cancer biology and potential therapeutic target. Cell communication and signaling : CCS 24 38326807
2018 PRMT1 mediates RANKL-induced osteoclastogenesis and contributes to bone loss in ovariectomized mice. Experimental & molecular medicine 24 30154485
2020 PRMT1 Is Critical for the Transcriptional Activity and the Stability of the Progesterone Receptor. iScience 23 32563156
2024 PRMT1 promotes Warburg effect by regulating the PKM2/PKM1 ratio in non-small cell lung cancer. Cell death & disease 22 39009589
2021 Arginine Methyltransferase PRMT1 Regulates p53 Activity in Breast Cancer. Life (Basel, Switzerland) 22 34440533
2024 PRMT1 acts as a suppressor of MHC-I and anti-tumor immunity. Cell reports 21 38401121
2022 TIPE1 inhibits osteosarcoma tumorigenesis and progression by regulating PRMT1 mediated STAT3 arginine methylation. Cell death & disease 21 36151091
2025 PRMT1-Mediated PARP1 Methylation Drives Lung Metastasis and Chemoresistance via P65 Activation in Triple-Negative Breast Cancer. Research (Washington, D.C.) 20 40927753
2024 LPCAT2 inhibits colorectal cancer progression via the PRMT1/SLC7A11 axis. Oncogene 20 38605214
2024 PRMT1 promotes epigenetic reprogramming associated with acquired chemoresistance in pancreatic cancer. Cell reports 20 38691454
2023 PRMT1 methylates METTL14 to modulate its oncogenic function. Neoplasia (New York, N.Y.) 20 37269817
2023 PRMT1 promotes the proliferation and metastasis of gastric cancer cells by recruiting MLXIP for the transcriptional activation of the β-catenin pathway. Genes & diseases 20 37554218
2019 Downregulation of PRMT1 promotes the senescence and migration of a non-MYCN amplified neuroblastoma SK-N-SH cells. Scientific reports 20 30741995
2024 Role of PRMT1 and PRMT5 in Breast Cancer. International journal of molecular sciences 19 39201539
2021 The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progression. Medicine 19 34516499
2021 Naturally occurring cancer-associated mutations disrupt oligomerization and activity of protein arginine methyltransferase 1 (PRMT1). The Journal of biological chemistry 19 34688662
2020 SCYL1 arginine methylation by PRMT1 is essential for neurite outgrowth via Golgi morphogenesis. Molecular biology of the cell 19 32583741
2025 Predicting the molecular mechanism of ginger targeting PRMT1/BTG2 axis to inhibit gastric cancer based on WGCNA and machine algorithms. Phytomedicine : international journal of phytotherapy and phytopharmacology 18 40446574
2022 Design and Synthesis of Novel PRMT1 Inhibitors and Investigation of Their Effects on the Migration of Cancer Cell. Frontiers in chemistry 17 35755248
2020 Structural and biochemical evaluation of bisubstrate inhibitors of protein arginine N-methyltransferases PRMT1 and CARM1 (PRMT4). The Biochemical journal 16 32011657
2018 Prmt1 regulates craniofacial bone formation upstream of Msx1. Mechanisms of development 16 29727702
2018 Protein Arginine Methyltransferase PRMT1 Is Essential for Palatogenesis. Journal of dental research 16 29986157
2023 Protein arginine methyltransferases PRMT1, PRMT4/CARM1 and PRMT5 have distinct functions in control of osteoblast differentiation. Bone reports 15 37593409
2022 Functional Study of Leishmania braziliensis Protein Arginine Methyltransferases (PRMTs) Reveals That PRMT1 and PRMT5 Are Required for Macrophage Infection. ACS infectious diseases 15 35226477
2022 A peptoid-based inhibitor of protein arginine methyltransferase 1 (PRMT1) induces apoptosis and autophagy in cancer cells. The Journal of biological chemistry 15 35764172
2022 Identification of Novel Circular RNAs of the Human Protein Arginine Methyltransferase 1 (PRMT1) Gene, Expressed in Breast Cancer Cells. Genes 15 35885916
2021 mTOR regulates PRMT1 expression and mitochondrial mass through STAT1 phosphorylation in hepatic cell. Biochimica et biophysica acta. Molecular cell research 15 33741434
2020 Effects of substrate modifications on the arginine dimethylation activities of PRMT1 and PRMT5. Epigenetics 15 33380261
2025 Opposing roles of p38α-mediated phosphorylation and PRMT1-mediated arginine methylation in driving TDP-43 proteinopathy. Cell reports 14 39817908
2024 Towards the Targeted Protein Degradation of PRMT1. ChemMedChem 14 38724444

Missed literature

Know a paper Affinage missed for PRMT1? Flag it for the maintainers and the community.

No submissions yet.